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Abstract
Oncogenic mutations in the mitogen activated protein kinase (MAPK) pathway are prevalent in human tumors, making this
pathway a target of drug development efforts. Recently, ATP-competitive Raf inhibitors were shown to cause MAPK
pathway activation via Raf kinase priming in wild-type BRaf cells and tumors, highlighting the need for a thorough
understanding of signaling in the context of small molecule kinase inhibitors. Here, we present critical improvements in cell-
line engineering and image analysis coupled with automated image acquisition that allow for the simultaneous
identification of cellular localization of multiple MAPK pathway components (KRas, CRaf, Mek1 and Erk2). We use these
assays in a systematic study of the effect of small molecule inhibitors across the MAPK cascade either as single agents or in
combination. Both Raf inhibitor priming as well as the release from negative feedback induced by Mek and Erk inhibitors
cause translocation of CRaf to the plasma membrane via mechanisms that are additive in pathway activation. Analysis of Erk
activation and sub-cellular localization upon inhibitor treatments reveals differential inhibition and activation with the Raf
inhibitors AZD628 and GDC0879 respectively. Since both single agent and combination studies of Raf and Mek inhibitors are
currently in the clinic, our assays provide valuable insight into their effects on MAPK signaling in live cells.
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Introduction
The mitogen activated protein kinase (MAPK) pathway con-
taining Raf, Mek and Erk is a central downstream axis of Ras
signaling involved in Ras-driven transformation [1,2]. Ras and Raf
harbor activating mutations in 30% and 8% of human tumors,
respectively [3,4,5], making these oncoproteins critical targets for
oncology drug development.
Inhibitors of both Mek and Raf are currently in clinical trials.
Although Mek inhibitors have shown little benefit in the clinic,
likely due to a narrower therapeutic index [6], the BRafV600E
selective inhibitor PLX4032 has demonstrated strong efficacy in
treating metastatic melanoma [7]. Interestingly, incidences of
squamous cell carcinoma and keratocanthoma have been reported
in clinical trials of two selective Raf inhibitors [8], suggesting a
potential growth-promoting effect of these agents in BRaf wild
type (WT) tissues. Three recent studies have investigated such
ATP-mimetic Raf inhibitors in BRaf-WT cells, showing that these
inhibitors have the ability to activate MAPK signaling in cells with
WT BRaf [9,10,11]. This activation is attributed to inhibitor-
induced priming of the Raf kinase as indicated by Raf dimeri-
zation, targeting of Raf to plasma membrane (PM)-localized Ras
and subsequent downstream MAPK pathway activation. Although
there is significant promise in targeting the MAPK pathway as a
therapeutic strategy, the effects of small molecule kinase inhibitors
on normal and tumor cells must be well understood to ensure
success in the clinic.
Inactive Raf is located in the cytosol, but upon Ras activation,
Raf is recruited to the PM by Ras-GTP resulting in Raf activation.
Raf membrane translocation can act as a reliable reporter for Ras
activation. Classically, the Ras binding domain of Raf (RBD),
which binds selectively to GTP-bound Ras, has been used to bio-
chemically measure the extent of Ras activation via pull-down
experiments [12]. More recently, fluorescent protein fusions of
RBD or full-length Raf have been used to visualize Ras activation
through PM translocation of these reporter constructs [13,14,15].
Although imaging approaches provide a real-time readout of Ras
activity, only limited manual quantification and low-throughput
acquisition strategies to visualize Ras activation have been imple-
mented, making these approaches limited in scope. Other microscopy-
based approaches have been developed using fluorescent resonance
energy transfer (FRET) between fluorescently-labeled Ras and
GTP or RBD, or conformational changes in a dual-fluorescently
labeled Ras-RBD fusion [16,17,18]. Although these assays have the
advantage of direct biophysical detection of Ras binding, they have
yet to be implemented in large-scale studies.
In this study we have extended the capabilities of a Ras-driven
Raf redistribution assay by fluorescently labeling both Ras and Raf
in an inducible, bicistronic system, a critical step in automating the
detection of Ras activation and high-throughput analysis. We
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scale of these assays and scope of our study. We first characterized
a fragment of Raf containing the Ras binding domain and a
cysteine-rich domain, RBDCRD that shows high sensitivity for
activated Ras and can detect changes in endogenous Ras activity.
We further expanded the redistribution assay by adding fluo-
rescently labeled Mek and Erk to visualize the complete canonical
MAPK pathway, with Erk nuclear translocation serving as a
readout of downstream pathway activity. Finally, we applied these
assays to a systematic study of the effect of hundreds of dosing
conditions of Raf, Mek and Erk inhibitors alone and in com-
bination in order to better understand how these small molecule
inhibitors affect pathway activity.
Results
Building an image analysis platform for measuring Ras
activation
To better understand the mechanistic outcome of therapeuti-
cally targeting components of the MAP-kinase pathway, we set out
to develop a quantitative method for measuring Ras activation by
monitoring the interaction between Ras and Raf. KRas, one of
three Ras isoforms, was used because it is commonly mutated in
cancer and is targeted exclusively to the PM [19], simplifying
subsequent analyses. eCFP-KRas and Venus-CRaf were co-
transfected into HEK 293T cells and imaged via confocal
microscopy to collect cross-sectional images of cells. We achieved
good spatial resolution covering the equatorial PM and the
adjacent cytoplasm, a critical approach for subsequent automated
analysis (Figure S1a). As expected, both RBD (aa51-131) and full-
length CRaf showed little targeting to the PM when cotransfected
with WT KRas, but higher membrane localization when these
constructs were cotransfected with oncogenic KRasG12D (Figure
S1b). These data confirmed that either RBD or full-length CRaf
can act as detectors of over-expressed activated KRas in live cells.
To accurately measure the targeting of signaling components
that translocate to the PM upon activation, we developed an
image analysis program that uses object-based filtering to selec-
tively measure PM Ras activation. To accomplish this, we
identified the centroids of cells (see Methods) and masked the
PM using eCFP-KRas or PMem localization (Fig. 1a). Ratios of
PM/cytoplasmic localization were measured by scanning outward
from the nuclear centroid until reaching the PM, where a local
pixel intensity ratio was recorded, and this procedure was repeated
radially around each cell (Figure 1a, right panel). Our approach
allowed for the detection of very subtle changes in PM localization
by measuring local differences in intensity, thus decreasing the
effect of large-scale intensity variations and making the approach
amenable to high-content imaging studies. When cells transiently
co-transfected with eCFP-KRas and Venus-CRaf were subjected
to this pixel ratio measurement approach, oncogenic KRasG12D
caused an increase in both RBD and FL-CRaf targeting to the PM
(Figure S1b). We further tested the sensitivity of our membrane
targeting analysis program using HEK 293 cells that stably
expressed Akt1-Venus and a fluorescent PM reporter (eCFP-
PMem) (Figure S2). Although Akt1 visually showed only very
subtle PM targeting in a serum-dependent manner [20], analysis
using the pixel ratio program measured a significant increase in
PM targeting from 1.08 to 1.11 (p=0.019). Taken together, our
image analysis program allows for automated detection of PM
localization of fluorescently labeled proteins, facilitating large-scale
quantitative imaging-based studies.
Since the stoichiometric balance of Ras and Raf expression was
important for robust targeting of Raf to the PM (data not shown),
we designed an expression system that would allow for stable,
physiologically relevant and balanced expression of Ras and Raf.
This system includes an internal ribosomal entry sequence (IRES)
element for bicistronic expression of two open reading frames, a
Tet-On CMV promoter for inducible expression and an FRT
recombination site, allowing single integration events to generate
stable cells (Fig. 1b). Inducible expression was required to generate
a stable HEK 293 cell line expressing KRasG12D, since pro-
longed constitutive expression was cytotoxic (data not shown).
Inducible cell lines were generated for both WT eCFP-KRas and
eCFP-KRasG12D with Venus-CRaf (Fig. 1c). When the PM/
cytoplasmic ratio of these cell lines was measured, the standard
deviation in our measurement of PM targeting was much lower
than that of transiently transfected cells, with estimated Z-factors
of 0.69 and 0.09 respectively (Fig. 1d and Figure S1). In summary,
our inducible bicistronic FRT recombination vector system allows
for regulated, balanced and homogeneous expression of multiple
components of a signaling pathway, making it ideal for inter-
rogating their behavior in response to perturbation.
To validate the eCFP-KRasG12D/Venus-CRaf bicistronic
stable cell line and our automated analysis methods for the investi-
gation of PM targeting upon perturbations by small molecule
inhibitors, cells were dosed with a 10-point dilution curve of
MCP110, which was recently shown to disrupt Raf targeting to
Ras at the PM [21]. Using our system we were able to calculate
that MCP110 blocked PM recruitment of CRaf at an EC50 of
5.1 mM with an R
2 value of 0.963 (Fig. 1e and f), consistent with
previous results.
RBDCRD senses endogenous Ras GTP loading
When analyzing fragments of CRaf, we found strong PM
targeting of a fragment containing the RBD and adjacent cysteine
rich domain (RBDCRD, aa51-186) with both WT KRas and
KRasG12D; however, targeting was impaired upon transfection
with the dominant negative mutant KRasS17N (Figure S1b and
4c). In fact, when RBDCRD was transfected with only a PM
reporter (CAAX motif), partial membrane targeting was detected
with only endogenous WT Ras present (Fig. 2a). It has been
suggested that this fragment of CRaf shows increased affinity for
RasGTP due to the absence of the regulatory domain that is
present in full-length CRaf [22]. Recent cellular data suggest that
RBDCRD may be a sensor for endogenous Ras-GTP [13];
however, subsequent biophysical data have challenged this con-
clusion [23]. Given the potential utility of a live cell sensor for
activated endogenous Ras, we set out to confirm the ability of
RBDCRD to discriminate endogenous RasGTP from RasGDP.
To determine whether RBDCRD targeting to the PM was Ras-
dependent, NCI-H727 cells, which have amplified expression of
KRasG12D [24], were transfected with Venus-RBDCRD. When
KRas protein levels were reduced by siRNA (data not shown),
RBDCRD PM targeting decreased, causing a notable increase in
cytoplasmic intensity and suggesting the KRas-dependent target-
ing of RBDCRD (Fig. 2b,c). To test whether RBDCRD bound
preferentially to RasG12D, isogenic Hec1A cells in which either
the WT or G12D allele of KRas was deleted [25] were transfected
with Venus-RBDCRD. PM targeting of RBDCRD was higher
in the Hec1A
KRasG12D/2 cell line when compared to the
Hec1A
KRasWT/2 cells, suggesting that RBDCRD does bind pre-
ferentially to activated KRas expressed at endogenous levels
(Fig. 2d). We next generated a 293 TRex
TM cell line expressing
Venus-RBDCRD and mCherry-PMem (for PM masking in the
absence eCFP-KRas expression). Due to lower steady state
expression compared to transiently transfected cells, RBDCRD
almost entirely targeted to the PM in these cells (Figure S4a and b).
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RasGTP levels, RBDCRD-expressing cells were transfected with
eCFP-KRasS17N, a dominant negative KRas mutant that depletes
endogenous RasGTP by sequestering Ras GEFs [26]. KRasS17N
expression caused a decrease in RBDCRD targeting to the PM,
which was further decreased by serum starvation (Figure S4b,c). We
next stimulated serum starved 293T cells transfected with Venus-
RBDCRD with epidermal growth factor (EGF), and monitored
RBDCRD PM translocation using time-lapse imaging (Fig. 2e and
Figure S4d). It has been suggested that RBDCRD remains locked
on the membrane once recruited by Ras [23]. To test this in our
system we dosed RBDCRD stable transfectants with MCP110
(Figure S5a and b). Displacement from the PM was seen at similar
doses as for FL-Craf, suggesting that RBDCRD interaction with
Ras at the PM can be disrupted. Together, these data confirm that
RBDCRD does indeed act as a sensitive sensor of Ras GTP biding,
allowing the monitoring of endogenous increases in Ras activity.
The data also demonstrate the improved sensitivity of our imaging
platform over existing imaging assays for monitoring physiologically
relevant changes in RasGTP levels.
Raf priming and MAPK feedback
We have previously used a qualitative, transient transfection Raf
redistribution assay to characterize the priming effect of the ATP-
Figure 1. Automated Ras-mediated Raf redistrbution analysis. (A) Graphical representation of raw data from Raf-redistribution assay analysis
(left, mCherry-KRas in red, Venus-CRaf in green) nuclear and PM masking (center) and radial intensity ratio scanning (right) show image analysis
approach. Scale bar is 20 mm and applies to all panels. (B) Schematic of bicistronic vector used to generate stable cell lines. (C) Images of bicsitronic
Flp-In stable cell lines expressing Venus-CRaf with eCFP-KRasWT and eCFP-KRasG12D. Cells were stained with Hoechst to demonstrate the
percentage of cells that express the fluorescent-fusion proteins (.99% for both cell lines). Scale bars are 20 mm and apply to corresponding
magnifications in all panels. (D) CRaf PM/cytoplasmic ratio measurement of KRasWT and KRasG12D stable cell line, p,0.001. (E) eCFP-KRasG12D and
Venus-CRaf expressing cells were treated with a serial dilution of MCP110 between 100 mM and 24 nM for 2.5 hrs, example images shown. Scale bar
is 20 mm and applies to all panels. (F) CRaf PM/cytoplasmic intensity ratios were measured for MCP110 serial dilution in (E).
doi:10.1371/journal.pone.0022607.g001
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PM targeting [9]. To better compare the potencies of these Raf
inhibitors on PM targeting of Craf, we utilized the improved
quantitative assay described above to calculate EC50s for each
compound (Fig. 3b). For these studies we used our KRasG12D/
CRaf cell line that showed an intermediate basal level of CRaf
targeting to the PM that, in turn, facilitates monitoring of Raf
recruitment to and displacement from the PM. While all Raf
inhibitors tested induced CRaf PM targeting, in the case of
GDC0879 and AZD628 targeting of CRaf to the PM appeared
to be nearly complete (Fig. 3a). The relative potencies of Raf
inhibitors on CRaf membrane targeting correlated well with their
estimated biochemical potencies against CRaf at physiological
ATP concentrations (Fig. 3d) [9]. Subtle, but significant, increases
in PM targeting were also measured when cells were treated with
the Mek inhibitor PD0325901 (Mek-i A) (Fig. 3b). To determine
whether this effect was similar for other MAPK pathway inhi-
bitors, we tested an additional Mek inhibitor (Mek-i B) [27] and an
Erk inhibitor (Erk-i) [28] (Fig. 3c). Both Mek-i A and Mek-i B as
well as the Erk-i caused a dose-dependent increase in CRaf PM
targeting. We hypothesized that the recruitment of CRaf to the
PM was due to releasing negative feedback that is triggered by
active Erk, acting directly on CRaf as well as RasGTP levels
[29,30]. Indeed, both Mek and Erk inhibitors were effective in
blocking downstream MAPK signaling in our engineered cell
line at doses that induced CRaf PM translocation, as shown by
immuno-fluorescence for phosphorylated ERK (Fig. 3e). As pre-
viously reported[9], the Raf inhibitors GDC0879 and PLX4720
caused an increase in pERK (Fig. 3e). Although AZD-628 induced
CRaf PM targeting, CRaf activity and therefore pERK levels were
decreased, which is consistent with our previous studies (Fig. 3e)
[9]. As expected, while both Mek and Erk inhibitors effectively
decreased phosphorylation of the ERK targets RSK (Thr359/
Ser363) and CRaf (ser289, Ser290, Ser304), Raf inhibitors had no
such effect (Figure S6 and data not shown). This confirms that our
system is sensitive enough to allow monitoring of both Raf
inhibitor priming and MEK/ERK inhibitor negative feedback
release.
Next, we hypothesized that there might be kinetic differences in
CRaf PM targeting caused by Raf priming versus negative
feedback release. To test this, RasG12D/CRaf cells were imaged
every 3 minutes after dosing with the Raf inhibitor GDC0879 or
Mek-i A (Fig. 3f). PM targeting of CRaf occurred immediately
after GDC0879 addition, whereas Mek-i A-induced PM targeting
Figure 2. CRaf RBCRD detects endogenous RasGTP. (A) HEK 293T cells were transfected with Venus-RBDCRD, eCFP-CAAX PM reporter (PMem),
and mCherry-H2B to label nuclei. Scale bar is 20 mm and applies to all panels. (B) KRas protein levels were reduced in NCI-H727 cells using 2 different
siRNA oligos against KRas or control oligo and then transfected with Venus-RBDCRD. Scale bar is 20 mm and applies to all panels. (C) Quantification of
RBDCRD PM targeting in NCI-H727 with KRas siRNA. (D) Hec1A isogenic cell ines (Parental, Ras
WT/- and Ras
G12D/-) were transfected with Venus-
RBDCRD and imaged live. RBDCRD PM targeting was then measured for each cell line. (E) Serum starved HEK 293T cells were stimulated with 100 ng/
ml EGF, and imaged every 15 sec, PM targeting of RBDCRD was then measured.
doi:10.1371/journal.pone.0022607.g002
Imaging Assays: Inhibitor Effects on MAPK Pathway
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e22607occurred after 36 minutes, suggesting that a switch-like accumu-
lation of feedback release is required to induce CRaf PM targeting.
Such switch-like responses are often dependent on relative con-
centrations of signaling components [31]. Accordingly, this
observed delay in CRaf targeting resulting from feedback inhibition
is reduced by increased expression level of Mek1 and Erk2 in a
KRasG12D/CRaf context (Figure S7). In conclusion, although Raf
priming andMek/Erkfeedbackreleaseboth lead toRaftargetingto
the PM, mechanistic differences between the two processes can be
elucidated by localization-based studies and further refined by
incorporating a temporal analysis into a high-content quantitative
end-point analysis.
Additive effect of priming and feedback inhibition
Based on our priming studies described above, we hypothesized
that since mechanisms for Raf PM targeting differ for Raf
Figure 3. Raf priming and MAPK negative feedback inhibition act to recruit CRaf to the PM. (A) The Raf inhibitors AZD628, GDC0879 and
PLX4720 along with Mek-i A were dosed in eCFP-KRasG12D and Venus-CRaf expressing HEK 293 cells, example images shown. Scale bar is 20 mm and
applies to all panels. (B) PM/cytoplasmic CRaf intensity for images such as those in (A) was measured 4 hours after compound addition. (C) Mek-i A was
compared to Mek-i B and Erk-i in CRaf redistribution assay. (D) Chart shows EC50 values for both the CRaf PM targeting assay and biochemical kinase
activity. (E) Cytoplasmic pERK was measured in cells dosed wih Raf, Mek and Erk inhibitors by immuno-fluorescence. (F) Kinetics of Raf inhibitor priming
and feedback were compared by conducting time lapse analysis of cells treated with GDC0879 and Mek-i A, frames acquired every 2 min.
doi:10.1371/journal.pone.0022607.g003
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an additive effect on CRaf PM levels. To test this hypothesis, we
treated RasG12D/CRaf expressing cells with each Mek and Erk
inhibitor in the presence of different Raf inhibitors at ,EC50
doses. Indeed, the Mek inhibitors and the Erk inhibitor all showed
an additive effect on CRaf PM targeting in combination with each
of the Raf inhibitors as indicated by an increase in maximal effect
without a large shift in EC50 (Fig. 4a–c) [32]. The additive effect
between Raf and Mek inhibitors on CRaf PM translocation was
observed when measuring CRaf/BRaf hetero-dimerization and
CRaf kinase activation induced by GDC0879 in the KRasG12D/
CRaf cells (Fig. 4d) as well as in H226 NSCLC cells where only
endogenous proteins are expressed (Figure S8). To determine
whether this additive effect on CRaf activity may have functional
downstream consequences, we treated Ras/Raf
WT tumor cells
with GDC0879 +/2 Mek-i A and measured cell proliferation.
Combination with GDC0879 blocked the anti-proliferative effect
of Mek-i A administered at low doses (Fig. 4e). These results
suggest that PM translocation of CRaf is a relevant marker of
pathway activation, leading to cellular hyperproliferation down-
stream of Raf inhibitor treatment of BRaf
WT cells.
Next, we tested combinations of Raf inhibitors, since each of
them has distinct binding modes to Raf [9]. Interestingly, the Raf
inhibitor AZD628 has synergistic activity in combination with the
Raf inhibitors GDC0879 and PLX4720 as indicated by a large
decrease in EC50 [32], whereas the combination of GDC0879 and
PLX4720 did not have a synergistic effect (Figure S9a–c). Synergy
between AZD628 and GDC0879 or PLX4720 was also seen when
looking at CRaf-BRaf heterodimerization and CRaf kinase activity
(Fig. S9 d and e). The difference between Raf inhibitor com-
bination effects might be due to the preferred Raf binding con-
formation for each compound: AZD628 binds to the inactive
conformation (DFG-out) of Craf, whereas both GDC0879 and
PLX4720 bind to the active CRaf conformation (DFG-in) [9],
with PLX4720 causing a c-helix shift that may block BRaf:CRaf
heterodimer formation, as observed in our current study. Such
detailed analysis for structurally dissimilar inhibitors of a common
target may provide further insight into their mechanistic
differences (Fig. 4f).
Effect of MAPK pathway inhibitors on RBDCRD cell line
To investigate how endogenous Ras activation is affected by
various MAPK pathway inhibitors, different inhibitor classes were
administered to HEK 293 TRex cells expressing RBDCRD.
These cells should respond to increased RasGTP levels but not to
Raf inhibitor priming, since RBDCRD lacks the Raf ATP binding
pocket (Fig. 5a). As predicted, both Mek and Erk inhibitors
induced an increase in PM targeting of RBDCRD consistent with
the release of negative feedback and an increase in RasGTP levels.
Surprisingly, the three Raf inhibitors caused a decrease in
RBDCRD PM targeting, suggesting that endogenous Raf, once
primed by Raf inhibitors, can displace RBDCRD from Ras at the
PM. Consistent with this model, pERK levels in the RBDCRD
cell line increased with the addition of Raf inhibitors but not Mek
inhibitors (Fig. 5b). However, when a Raf inhibitor was combined
with either Mek or Erk inhibitors, the displacement of RBDCRD
seen with Raf inhibitor alone was abolished. Instead, RBDCRD
was recruited to the membrane to a degree similar to that induced
by Mek and Erk inhibitors alone, suggesting that Ras activation
may lock RBDCRD at the PM before priming-induced displace-
ment of RBDCRD can occur (Fig. 5c).
We next used kinetic experiments to further characterize the
effects of negative feedback release vs. priming in the RBDCRD
cell line and understand the interaction of RBDCRD with
RasGTP. Addition of Mek-i A caused recruitment of RBDCRD
to the PM within 1.5 min., whereas the onset of RBDCRD dis-
placement after addition of GDC0879 occurred after 7.5 min.
(Fig. 5d). When GDC0879 andMek-i A werecombined, RBDCRD
recruitment was similar to that of Mek-i A alone. Furthermore,
when GDC0879 and Mek-i A were added sequentially during time-
lapse imaging with a 28.5 minute interval between compound
additions, the initial displacement of RBDCRD from the PM was
fully recovered upon Mek-i A addition (Fig. 5E). Based on our
findings, we propose a model whereby RBDCRD does not readily
release from Ras upon GTP hydrolysis. This idea is supported by
the lack of reversibility of RBDCRD PM targeting upon EGF
stimulation (Fig. 2e) as well as in vitro biophysical data [33]. Notably,
recent work has demonstrated that RBDCRD binding to WT Ras
orRasG12V doesnoteffect ratesofhydrolysis[34].A lackofrelease
from RasGDP would also explain why RBDCRD is so highly
enrichedatthePMincellswithendogenousRas,whereonlyasmall
fraction of Ras is GTP-bound at any given time. Over time, the
stochastic activation of Ras should lead to a large accumulation of
RBDCRD at the PM. Supporting this idea, when RBDCRD PM
targeting is measured upon RBDCRD induction in the HEK 293
stable cell line, maximal PM targeting is seen only after 10 h of
induction (Figure S5c). Taken together, our study of RBDCRD
reveals a novel mechanistic model to explain the unique cellular
behavior of this fragment of CRaf (Fig. 5f).
Visualizing the MAPK pathway
Finally, since KRas and CRaf are expressed at higher than
endogenous levels in the inducible HEK293 cell line (Figure S3),
we wanted to increase the expression levels of Mek and Erk to
determine whether feedback signaling to Raf was affected.
TagBFP-Mek1 and mCherry-Erk2 were added to the Ras/Raf
cell line using the pIRES3 vector system. Mek1 and Erk2 were
both primarily localized in the cytoplasm in the absence of eCFP-
KRasG12D and Venus-CRaf induction. Upon KRasG12D/CRaf
induction, Erk2 accumulated in the nucleus and pERK levels
increased, consistent with the expected induction of activity (Fig. 6a
and b and Figure S3) [35,36]. As expected, both Raf inhibitor
priming and Mek/Erk inhibitor negative feedback release caused
CRaf targeting to the PM in a dose-dependent manner in the
RasG12D/CRaf/Mek1/Erk2 cell line (Fig. 6c). No changes were
detected in the cytosolic localization of TagBFP-Mek1 (data not
shown). We next looked at the targeting of Erk to the nucleus by
measuring cytoplasmic versus nuclear intensities of mCherry-Erk2
and calculating the nuclear/cytoplasmic ratio. These ratios were
measured at the individual cell level since the expression level of
mCherry-Erk2 was variable. Mek-i A caused a decrease in nuclear
Erk as expected, whereas interestingly the Raf inhibitor GDC0879
caused a subtle but reproducible increase in nuclear Erk levels
(Fig. 6d). At high doses the Raf inhibitor AZD628 caused a
decrease in nuclear Erk, consistent with its biochemical potency on
CRaf [9]. Since the MAPK pathway is highly activated upon the
induction of KRasG12D and CRaf (Figure S3), we also looked at
nuclear Erk levels in the KRasG12D/CRaf/Mek1/Erk2 cell line
in the absence of KRasG12D and CRaf induction. In this setting,
the decreases in nuclear Erk seen with Mek-i A and AZD628
treatments were subtle, whereas the increase caused by GDC0879
was more dramatic than in the RasG12D/CRaf induced cells
(Fig. 6e). Since basal pERK levels were lower in uninduced cells,
the activating effect of GDC0879 on pERK became more
pronounced (Fig. 6f and g and Figure S10). Since pERK levels
correlated well with Erk2 nuclear localization in our studies, we
confirm previous reports that nuclear Erk acts as a reliable live-cell
readout of Erk activation [37]. Furthermore, our data suggest that
Imaging Assays: Inhibitor Effects on MAPK Pathway
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identify both suppressors and activators of Erk activity.
Discussion
Live cell microscopy assays are ideally suited for studying the
spatial and temporal aspects of cellular signaling. While quantita-
tive, high-throughput time-lapse microscopy has most commonly
been applied in the context of siRNA screens to identify modulators
of the cell cycle [38], our work highlights the utility of these
approaches to visualize compound-mediated perturbations of
pathway dynamics in a commonly mutated oncogenic signaling
pathway. We report advances in cell line engineering, image
acquisition and analysis that enabled us to carry out a high-
throughput investigation of a panel of inhibitors with diverse
specificity,potency,binding,andmechanismsofactionandperform
systematic and comprehensive analysis of their impact on pathway
activity individually and in combination within living cells.
We observed that inhibitors of MEK and ERK promote path-
way activation through release of negative feedback, consistent
Figure 4. Combination of Raf priming with Mek/Erk inhibition has an additive effect on MAPK signaling. (A) KRasG12D/CRaf HEK 293
cells were dosed with varying concentration of Mek-i A and constant dose of 12 nM AZD628, 2 mM PLX4720 or 300 nM GDC0879, as indicated, and
CRaf PM targeting was measured after 4 hrs. (B) CRaf PM targeting was measured for the combination of Mek-i B with 12 nM AZD628, 2 mM PLX4720
or 300 nM GDC0879. (C) CRaf PM targeting was measured for the combination of Erk-i with12 nM AZD628, 2 mM PLX4720 or 300 nM GDC0879. (D)
Top: Immunoblot of Braf:Craf heterodimers in cells treated with GDC-0879 (0.03, 0.1, 0.3, 1 mM) for 4 hours. Heterodimer formation observed with
GDC-0879 alone is further increased upon co-administration of 1 mM MEK inhibitor Mek-i A. Bottom: CRaf IP kinase activity assays from lysates of cells
treated as above. CRaf was immunoprecipitated from treated cells and kinase activity towards recombinant MEK was tested in vitro. Co-
administration of Mek-i A with GDC0879 resulted in a dose-dependent increase in maximal CRaf kinase activity across all GDC0879 doses. For the CRaf
kinase activity assays, relative phospho-MEK levels measured with MSD pMEK ELISA assay are shown. (E) Four-day proliferation curves of Ras
WT/Raf
WT
cells (SW48 colon carcinoma) upon combination treatment of GDC-0879 with increasing concentrations of Mek-i A show induction of viable cell
counts compared to MEK inhibitor treatment alone in a dose dependent manner with a maximal effect at co-administration of 1 mM of GDC0879. (F)
Model describing the localization effect of Raf, Mek and Erk inhibitors on Raf cellular localization. Ras activation causes CRaf recruitment to the PM,
priming of CRaf or inhibition of negative downstream feedback increase CRaf targeting to the PM. Combination of priming and feedback inhibition
additively promote CRaf PM targeting.
doi:10.1371/journal.pone.0022607.g004
Imaging Assays: Inhibitor Effects on MAPK Pathway
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e22607with previous data. Time-lapse experiments demonstrated that the
dynamics of pathway activation via the multistep process of
negative feedback release are slower and more stoichiometrically
regulated than direct pathway activation by Raf inhibitor priming.
Combination of Raf inhibitors with MEK or ERK inhibitors led to
an additive promotion of MAPK pathway activation through
the combined effects of negative feedback release and priming.
Furthermore, combination of two Raf inhibitors with different
modes of binding to Raf, e.g., AZD628 combined with either
GDC0879 or PLX4720, resulted in a synergistic increase in
pathway activation, whereas combination of inhibitors with similar
binding modes, i.e., GDC0879 and PLX4720, did not result in
synergy. In future studies, it would be interesting to investigate the
localization dynamics and MAPK activity using reporters of
BRafV600E, as the Raf inhibitors used in this study have been
shown to act to block V600E activity [11]. In sum, these observa-
tions illustrate the potential of this approach to systematically
screen inhibitor combinations with diverse specificities, potencies
and binding modes to exclude those with undisirable effects and to
identify those that are most likely to offer maximum therapeutic
benefit.
Regarding RBDCRD, a fragment of CRaf that has been
reported to be a sensor of endogenous activated Ras [13], a claim
that has been disputed by more recent work [23], we confirmed its
ability to sense endogenous RasGTP in several cell types and
generated an RBDCRD reporter cell line for use in subsequent
quantitative high throughput analysis. Subjecting this cell line to
inhibitors that promote priming or release negative feedback or
combinations thereof allowed us to detect differential effects of
feedback and priming mediated by endogenous proteins and
supported a refined model for the mechanism of RBDCRD
binding to and release from Ras. Our data are consistent with a
model in which the RBDCRD off-rate from Ras is much slower
than that of full-length CRaf, which can reconcile the ability of the
RBDCRD fragment to detect endogenous RasGTP levels driven
by the release of negative feedback from the membrane
displacement of RBDCRD seen with inhibitor-induced Raf
priming.
Figure 5. RBDCRD response to MAP-kinase inhibitors. (A) RBDCRD PM targeting was measured in Venus-RBDCRD stable cell line after 4 hr
treatment with AZD628, GDC0879, PLX4720, Mek-i A, Mek-i B, or Erk-i. (B) phospho-ERK intensity was measured by immuno-fluorescence in cells
treated as in (A). (C) RBDCRD PM targeting was measured in cells treated with a constant dose of 250 nM GDC0879 with a dose curve of the other
small molecule inhibitor, showing the dominant effect of Mek and Erk inhibitor-induced targeting. (D) Time-lapse experiments show the kinetics of
RBDCRD PM targeting and displacement upon treatment with 250 nM GDC0879, 20 nM Mek-i A or the combination of both. (E) Time-lapse
experiment as in (D) where GDC0879 and Mek-i A were added sequentially with a 28.5 min. time gap between compound additions. (F) Schematic
model describing RBDCRD cellular behavior in the presence of MAPK inhibitors.
doi:10.1371/journal.pone.0022607.g005
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strategies for targeting dysregulated oncogenic signaling pathways.
Although the relevance of the intracellular environment to the
activity of these pathways is becoming increasingly appreciated
[39], in the absence of appropriate cell-based assays, typical drug
discovery efforts are predicated on in vitro mechanistic biochemical
assays followed by non-mechanistic cell viability assays that do not
offer insight into the subtleties of drug mechanism of action in
live cells. An inherent risk in this strategy is highlighted by the
observation cited above that Raf inhibitors prime Raf in certain
cellular contexts, thus promoting therapeutically undesirable
MAPK pathway activation. Our data indicate that mechanistic
cellular assays that can detect inappropriate pathway activation
in a cellular environment and are amenable to high-throughput
analysis can be an important tool in effectively prioritizing the
development of safe and efficacious targeted drugs and in iden-
tifying productive therapy combinations.
Materials and Methods
Molecular biology
Fluorescent fusion proteins were generated using two-insert
multisite GatewayH cloning (Invitrogen) where one insert con-
tained the fluorescent protein tag and the other contained gene of
study, these constructs where inserted into pCDNA-DEST47 with
a stop codon to prevent translation of the c-terminal GFP. An
IRES element was inserted into the middle of the multiple cloning
site of pCDNA5/FRT/TO (pFIT), fluorescent-fusion genes were
then cloned into the pFIT vector on both sides of the IRES using
In-Fusion PCR cloning (Clontech). For the construction of the
eCFP-KRasG12D Venus-CRaf TagBFP-Mek1 mCherry-Erk2
cell line, the GatewayH cassette was added to the pIRES3 vectors
(Clontech) using the GatewayH conversion system (Invitrogen) and
the fluorescent fusion constructs for Mek1 are Erk2 were inserted
using multisite Gateway.
Cell line engineering and culturing
HEK 293T (ATCC
TM) were grown in DMEM-F12 50:50
media with 10% fetal bovine serum (FBS) and 1X Glutamax
(Invitrogen
TM), HEK 293 TRex cells (Invitrogen
TM) were cultured
in DMEM-F12 50:50 with 10% Tet-free FBS and 1X Glutamax.
NCI-H727 (ATCC
TM) were cultured in RPMI with 10% FBS and
1X Glutamax, Hec1A [25] cells were grown in McCoy’s media
with 10% FBS and 1X Glutamax. Allcelllines were cultured at 37uC
with 5% C02. Transient transfections were carried out in HEK293T,
NCI-H727 and Hec1A cells were done using Lipofectamine2000
(Invitrogen
TM) using the manufactures suggested protocol. T-REx
TM
cell lines were made following the manufactures protocol (Invitro-
gen
TM). pIRES3 vectors were transfected into T-REx
TM stable cell
lines,drugselection[100 mg/ml Geneticin or 500 ng/ml puromycin]
was added 2 days after trasfection. For microscopy-based assays, cells
were plated at 13,000–22,000 cells per well in coverslip-bottom 384
well plates (Aurora Biotechnologies). For experiments involving the
HEK 293 T-REx
TM cell lines, cells were induced with 1 mg/ml
Doxycycline 24 hrs after cell plating and 20–30 before imaging.
Compounds were added 2.5–4 hrs prior to imaging for end-point
assays or after three frames of acquisition for time-lapse studies.
Microscopy
384 well plates were imaged with a Nikon Ti-perfect focus
inverted micrscope with an A1R resonant spectral confocal system
with temperature and environmental (37uC5 %C O 2) control.
Figure 6. Visualization of the labeled MAPK pathway. (A) Example images show induced parental KRasG12D/CRaf cell line, induced and
uninduced 4-color cell line where TagBFP-Mek1 and mCherry-Erk2 are constitutively expressed. Scale bar is 20 mm and applies to all panels. (B)
Nuclear localization of TagBFP-Mek1 and mCherry-Erk2 was measured in MAPK cell line where eCFP-KRasG12D and Venus-CRaf were either induced
or uninduced. (C) MAPK cell line was dosed with Raf, Mek and Erk inhbitors, CRaf PM localization was measured. (D) The nuclear/cytoplasmic ratio of
mCherry-Erk1 was measured in MAPK cell line where KRasG12D and CRaf expression were induced. (E) The nuclear/cytoplasmic ratio of mCherry-Erk1
was measured in the MAPK cell line where KRasG12D and CRaf were not induced. (F) Nuclear pERK was measured in the HEK 293 KRasG12D/CRaf/
Mek1/Erk2 cell line by immuno-fluorescence 5hrs after inhibitor treatment. (G) Nuclear pERK was measured as in (F) in the HEK 293 cell line
expressing TagBFP-Mek1 and mCherry-Erk2 where expression of KRasG12D and CRaf is not induced.
doi:10.1371/journal.pone.0022607.g006
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308 wells of the plate were used for acquistion. Most images were
acquired with a CFI Plan Fluor 40X oil immersion objective (NA:
1.3, Nikon), full plate acquisition was possible by first spreading
37uC immersion oil (Cargille) on the plate bottom with an ink
roller. Ti-Perfect focus functionality was used to ensure proper oil
interface was maintained between plate bottom and objective, with
a custom-built macro used to correct loss in interface (Austin
Blanco, Technical Instruments). Low-resolution images of pERK
experiments were acquired with a CFI Plan Apo VC 20X
objective (NA: 0.75, Nikon).
Image and Data Analysis
Custom image analysis programs were written in MATLABH
(MathWorksH) to segment cells into PM, cytoplasm/nuclear
compartments and subsequently measure fluorescent intensity
within each of these compartments (see Materials S1). Cellular
centroids were identified by either the nuclear absence of Venus-
CRaf, the absence mCherry-PMem signal in the nuclear and
cytoplasmic space or by the presence of fluorescently labeled H2B.
For PM targeting measurements, 360 pixel ratios at the PM and
adjacent cytoplasm were measured per cell, 2 fields of ,200–400
cells per field were analyzed per condition. Experimetns were
repeated as three biological replicates and data from each experei-
ment was combined to graphing. For nuclear ERK targeting the
nuclear/cytoplasmic ratio of mCherry-Erk2 was measured in
individual cells and then averaged per field. Nuclear and cyto-
plasmic pERK intensity were measured in bulk per image.
Numerical data generated from image analysis was plotted and
fitted using Excel (Microsoft) and Prism (Graph Pad). Dose-curve
experiments were fitted with a variable slope sigmoid curve and
time-lapse experiments were fit to a single exponential. All error
bars represent standard error and p-values were calculated using
T-test.
Biochemical Experiments
Biochemical experiments were conducted as described in
Hatzivassiliou et al. [9].
Supporting Information
Figure S1 Membrane targeting of CRaf and CRaf
fragments with KRas. (A) 293T cells were transfected with
either eCFP-KRasWT or eCFP-KRasG12D together with Venus-
CRaf RBD, Venus-FL-CRaf or Venus-CRaf RBDCRD and
mCherry-H2B. Scale bar is 20mm and applies to all panels. (B)P M
targeting of transient transfection experiment described in (A) was
measured, along with cells transfected with eCFP-KRasS17N, a
dominant negative mutant, and eCFP-CAAX as a PM reporter.
(TIFF)
Figure S2 Akt1 stable cell line show subtle serum-
dependent PM targeting. (A) A stable 293 T-REx
TM cell line
expressing Venus-Akt1 and eCFP-PMem (CAAX motife) was
generated, example images of cells starved of serum for 12hrs or
with 10% FBS are shown. Scale bar is 20mm and applies to all
panels. (B) PM targeting of Venus-Akt1 was measured +/- serum
using automated PM targeting program, p=0.016.
(TIFF)
Figure S3 Western blot analysis of 293 T-REx
TM stable
cell lines. Cells were either cultured without doxycycline or induced
with 100ng/ml doxycycline for 24hrs before harvesting cell lysates. (A)
Expression of both Venus-fusion and eCFP-fusion constructs were
detected using an anti-GFP antibody, Venus-RBDCRD migrated
faster than eCFP-KRas and the larger Venus-CRaf. (B)B o t h
endogenous and Venus-CRaf were detected with anti-CRaf
antibody, showing strong Tet-repression in the absence of Dox. (C)
Cell lysates expressing both endogenous Ras and eCFP-KRas were
probed with an anti-KRas antibody.
(TIFF)
Figure S4 RBDCRD PM Targeting. (A) HEK 293T cells
were transfected with Venus-RBDCRD and cells with varying
expression of were imaged (top row), when intensites were nor-
malized (bottom row) inverse correlation with PM targeting and
expression level was seen suggesting a limited number of RBDCRD
binding sites at the PM. Scale bar is 10mm and applies to all panels.
(B) HEK 293 T-REx
TM Venus-RBDCRD, mCherry-PMem stable
cellline was generated, and images were acquired for cells grown with
serum, cells which were starved of serum for 12hrs and for cells
transientlytransfected withthedominant negativeeCFP-KRasS17N.
(C) RBDCRD PM targeting was measured for experiment described
in (B). Scale bar is 20mm and applies to all panels. (D)E x a m p l e
images for EGF stimulation of HEK 293T cells transfected with
Venus-RBDCRD quantified in Figure 2E. Scale bar is 20mma n d
applies to all panels.
(TIFF)
Figure S5 MCP110 disrupts RBDCRD PM targeting. (A)
HEK 293 T-REx
TM Venus-RBDCRD cell line was treated with
MCP110 and images were acquired after 2.5hrs. Scale bar is
20mm and applies to all panels. (B) Venus-RBDCRD PM targeting
was measured for cells dosed with MCP110. (C) HEK 293 T-
REx
TM Venus-RBDCRD cell line was induced with doxycycline
and imaged every 30min, PM/cytoplasmic ratios of RBDCRD
were then measured.
(TIFF)
Figure S6 Dose dependent MAPK pathway inhibition by
MEK (Mek-i A, Mek-I B) and Erk-i inhibitors (panel A)
leads to release of negative feedback MAPK phosphor-
ylation site on CRaf (panel B). Cells were treated with
indicated inhibitor concentrations for 4 hours and lysates probed
by immunoblot for pRSK (T359/363) and pCRaf(S289/296/301)
levels (bottom). Curves represent quantitation of WB with
Typhoon and curve fitting using Prism. (C,D) Western blot
images of (A) and (B) respectively.
(TIFF)
Figure S7 CRaf PM targeting is rapid with Mek-i A in
KRasG12D/CRaf/Mek1/Erk2 cell line. MAPK cell line
was imaged with time-lapse micrscopy and CRaf PM targeting
was measured with the addition of 10mM GDC0879 or 10mM
Mek-i A, images were acquired every 2min.
(TIFF)
Figure S8 Additivity in targeting CRaf to the plasma
membrane through combined priming by RAF inhibi-
tors and negative feedback release by MEK inhibitors in
H226 (KRas
WT/CRaf
WT) NSCLC cells. Targeting CRaf to
the plasma membrane upon combined priming by RAF inhibitors
and negative feedback release by MEK inhibitors in H226
(KRas
WT/CRaf
WT) NSCLC cells. (A) Top: Immunoblot of
Braf:Craf heterodimers in H226 cells treated with GDC-0879
(0.1, 1, 10 mM) for 24 hours in cells pretreated for 1 hour with
either DMSO or 1 mM Mek-i A. Heterodimer formation observed
with Raf inhibitors alone is further increased upon co-adminis-
tration of 1 mM MEK inhibitor Mek-i A. Bottom: Western blot of
lysates from cells treated as above with indicated antibodies
showing induction of pCRaf S338 and phospho-MEK levels. (B)
CRaf IP kinase activity assays from lysates of cells treated as above.
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PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e22607CRaf was immunoprecipitated from treated cells and kinase
activity towards recombinant MEK was tested in vitro. Co-
administration of Mek-i A with GDC-0879 resulted in a dose-
dependent increase in maximal CRaf kinase activity across all Raf
inhibitor doses. For the CRaf kinase activity assays, shown are
relative phospho-MEK levels measured with MSD pMEK ELISA
assay.
(TIFF)
Figure S9 The DFG-out Raf inhibitor AZD-628 syner-
gizes with the DFG-in inhibitors GDC-0879 and PLX4720
to potentiate CRaf activation in KRasG12D/CRaf 293 T-
REx
TM cells. Antagonism is observed between DFG-in
Raf inhibitor GDC-0879 and DFG-in/c-helix shift
PLX4720. (A) KRasG12D/CRaf HEK 293 T-REx
TM cells were
dosed with varying concentrations of AZD628 and constant dose
of 2mM PLX4720 or 300nM GDC0879 and CRaf PM targeting
was measured after 4hrs. (B) KRasG12D/CRaf HEK 293 T-
REx
TM cells were dosed with varying concentrations of GDC0879
and constant dose of 2mM PLX4720 or 12nM AZD628 and CRaf
PM targeting was measured after 4hrs. (C) KRasG12D/CRaf
HEK 293 T-REx
TM cells were dosed with varying concentrations
of PLX4720 and constant dose of 12nM AZD628 or 300nM
GDC0879 and CRaf PM targeting was measured after 4hrs. (D)
Top: Immunoblot of immunoprecipitated (IP) Craf shows
Braf:Craf heterodimers in cells treated with AZD-628 (0.001 and
0.01) for 4 hours. Heterodimers are further induced in the
presence of 50 nM GDC-0879 (middle panel) and reduced in the
presence of 1 mM PLX4720, which disrupts heterodimer forma-
tion due to induction of a c-helix shift in BRaf and CRaf. Bottom:
CRaf IP kinase activity assays from lysates of KRasG12D/Craf
293 T-REx
TM cells treated with 0.001 and 0.01 mM AZD-628 for
4 hours. CRaf was immunoprecipitated from treated cells and
kinase activity towards recombinant MEK was tested in vitro. (E)
Top: Immunoblot of BRaf:CRaf heterodimers in cells treated with
PLX4720 (0.1, 1, 10) for 4 hours. Weak heterodimer formation
observed with PLX4720 alone, compared to treatment with 300
nM GDC-0879 alone (5th lane, DMSO/GDC-0879 panel).
Increasing amounts of PLX4720 further destabilize BRaf:CRaf
heterodimers due to distinct binding mode of PLX4720. Bottom:
CRaf IP kinase activity assays from lysates of cells treated with
PLX4720 (0.1, 1, 10) for 4 hours. CRaf was immunoprecipitated
from treated cells and kinase activity towards recombinant MEK
was tested in vitro. Adding PLX4720 to GDC-0879 treated cells
leads to a dose-dependent decrase in maximal CRaf kinase
activity. For all Craf kinase activity assays, relative phospho-MEK
levels measured with an MSD pMEK ELISA assay are shown.
(TIFF)
Figure S10 Images of mCherry-Erk1 localization and
phospho-ERK. (A) Example images of mCherry-Erk2 sub-
cellular localization, imaged 4hrs after inhibitor treatments with
KRasG12D and CRaf induced. Scale bar is 20mm and applies
to all panels. (B) Example images of mCherry-Erk2 sub-cellular
localization, imaged 4hrs after inhibitor treatments with KRasG
12D and CRaf uninduced. Scale bar is 20mm and applies to all
panels. (C) Example images of pERK immuno-fluorescence,
stained and imaged 5hrs after inhibitor treatments with KRas
and CRaf induced. Scale bar is 20mm and applies to all panels. (D)
Example images of pERK immuno-fluorescence, stained and
imaged 5hrs after inhibitor treatments with KRas and CRaf
uninduced. Scale bar is 20mm and applies to all panels.
(TIFF)
Materials S1 Matlab Programs.
(DOCX)
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